Home » Topics » BioWorld Science, Neurology/psychiatric

BioWorld Science, Neurology/psychiatric
RSS

ATAD3A is a therapeutic target in Alzheimer's disease

June 2, 2022

Close look illuminates ketamine's (relative) staying power

June 1, 2022

Artemisinin derivatives as potential agents for the treatment of MS

June 1, 2022

Studies identify chronic pain mechanisms in skin and spinal cord

May 31, 2022

PharmEnable and Denali Therapeutics to collaborate in neurodegenerative disease research

May 31, 2022

Boehringer Ingelheim presents new indoleamine 2,3-dioxygenase 1 inhibitors

May 31, 2022

Suzhou Yabao Pharmaceutical Research and Development patents mutant LRRK2 inhibitors

May 31, 2022

NRG Therapeutics receives Biomedical Catalyst award for neurodegenerative disorders

May 31, 2022

Morc2 S87L mutation in mice mimics human Charcot-Marie-Tooth disease

May 30, 2022

NLRP3 inflammasome inhibitor INF-176 for the treatment of Alzheimer's disease

May 30, 2022

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 17, 2026.
ALN-5288 lowers tau levels in preclinical models
BioWorld Science
Pathological tau accumulation is a key driver of neurodegeneration in Alzheimer’s disease (AD) and other tauopathies such as progressive supranuclear palsy....
Dual FAAH/MAGL inhibition targets Alzheimer’s disease hyperexcitability
BioWorld Science
Reduced endocannabinoid signaling has been linked to neuronal hyperexcitability in Alzheimer’s disease (AD), suggesting that dual inhibition of fatty acid amide...
Capital remains selective in ‘barbell’ biotech market
BioWorld
Signs of recovery are emerging in the biotechnology investment sector, although investors across Asia say that capital is flowing selectively to companies that...
PSB-229 reduces plaque burden in Alzheimer’s models
BioWorld Science
Pyroglutamate-modified amyloid-β (pE3-Aβ) is a highly pathogenic Aβ species that accumulates within amyloid plaques and contributes to aggregation,...